CN102917590B - 三环化合物及含有所述化合物的pbk抑制剂 - Google Patents

三环化合物及含有所述化合物的pbk抑制剂 Download PDF

Info

Publication number
CN102917590B
CN102917590B CN201180026805.8A CN201180026805A CN102917590B CN 102917590 B CN102917590 B CN 102917590B CN 201180026805 A CN201180026805 A CN 201180026805A CN 102917590 B CN102917590 B CN 102917590B
Authority
CN
China
Prior art keywords
quinolin
phenyl
hydroxy
quinoline
hydroxythieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180026805.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102917590A (zh
Inventor
中村佑辅
松尾洋
久田升二
F.阿梅德
R.亨特利
Z.萨加迪-哈舍米
D.M.詹金斯
R.B.卡格博
崔文革
P.J.F.盖乌安
J.R.瓦尔克
H.德科尔内兹
M.古拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of CN102917590A publication Critical patent/CN102917590A/zh
Application granted granted Critical
Publication of CN102917590B publication Critical patent/CN102917590B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CN201180026805.8A 2010-03-29 2011-03-29 三环化合物及含有所述化合物的pbk抑制剂 Active CN102917590B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31860610P 2010-03-29 2010-03-29
US61/318,606 2010-03-29
PCT/US2011/030278 WO2011123419A1 (en) 2010-03-29 2011-03-29 Trycyclic compounds and pbk inhibitors containing the same

Publications (2)

Publication Number Publication Date
CN102917590A CN102917590A (zh) 2013-02-06
CN102917590B true CN102917590B (zh) 2016-02-17

Family

ID=44712585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180026805.8A Active CN102917590B (zh) 2010-03-29 2011-03-29 三环化合物及含有所述化合物的pbk抑制剂

Country Status (15)

Country Link
US (2) US8962648B2 (https=)
EP (1) EP2552206B1 (https=)
JP (1) JP5849302B2 (https=)
KR (1) KR101757502B1 (https=)
CN (1) CN102917590B (https=)
AU (1) AU2011235319B2 (https=)
BR (1) BR112012023836B1 (https=)
CA (1) CA2792941C (https=)
DK (1) DK2552206T3 (https=)
ES (1) ES2547571T3 (https=)
IL (1) IL222080B (https=)
MX (1) MX2012011412A (https=)
SG (1) SG184376A1 (https=)
TW (1) TWI503323B (https=)
WO (1) WO2011123419A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2857848T3 (es) * 2013-12-24 2021-09-29 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
TWI557011B (zh) 2015-05-25 2016-11-11 可影像處理的自行車錶裝置
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
EP3609869A1 (de) 2017-04-10 2020-02-19 Bayer Aktiengesellschaft Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung
WO2019094404A1 (en) * 2017-11-07 2019-05-16 Temple University-Of The Commonwealth System Of Higher Education Compositions and methods for improved t cells
CN111099941B (zh) * 2018-10-26 2022-10-18 中国科学院上海有机化学研究所 一种烷基腈类化合物的制备方法
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
WO2024008113A1 (zh) * 2022-07-07 2024-01-11 深圳微芯生物科技股份有限公司 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用
WO2024097228A1 (en) * 2022-10-31 2024-05-10 Meliora Therapeutics, Inc. Compounds targeting cdk11 and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166929A1 (en) * 1999-10-06 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
CA2501881A1 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
CN1704404A (zh) * 1999-12-29 2005-12-07 惠氏公司 三环蛋白激酶抑制剂
WO2006120573A2 (en) * 2005-02-01 2006-11-16 Sentinel Oncology Limited Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
US20090239859A1 (en) * 2008-02-29 2009-09-24 Chua Peter C Protein kinase modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5377096A (en) * 1976-12-17 1978-07-08 Teijin Ltd Preparation of thieno 2,3-c quinolin-4(5h)-one-7-acetic acids
FR2636063B1 (fr) * 1988-09-05 1993-04-30 Centre Nat Rech Scient Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application
DE19806348A1 (de) * 1998-02-12 1999-08-19 Schering Ag 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
DE10242106A1 (de) 2002-09-11 2004-04-15 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Phosphorgruppenhaltige Carbonsäurederivate mit organisch polymerisierbaren Gruppen
HRP20050248A2 (en) 2002-09-17 2005-10-31 Warner-Lambert Company Llc Heterocyclic substituted piperazines for the treatment of schizophrenia
US7956064B2 (en) * 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166929A1 (en) * 1999-10-06 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
CN1704404A (zh) * 1999-12-29 2005-12-07 惠氏公司 三环蛋白激酶抑制剂
CA2501881A1 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
WO2006120573A2 (en) * 2005-02-01 2006-11-16 Sentinel Oncology Limited Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
US20090239859A1 (en) * 2008-02-29 2009-09-24 Chua Peter C Protein kinase modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer》;Jae-Hyun Park，el.;《cancer research》;20060915;第66卷(第18期);9186-9195 *

Also Published As

Publication number Publication date
CN102917590A (zh) 2013-02-06
SG184376A1 (en) 2012-11-29
EP2552206A1 (en) 2013-02-06
RU2012145855A (ru) 2014-05-10
BR112012023836B1 (pt) 2022-02-01
HK1179114A1 (en) 2013-09-27
EP2552206A4 (en) 2013-08-14
CA2792941C (en) 2017-09-12
US9453025B2 (en) 2016-09-27
IL222080B (en) 2018-05-31
WO2011123419A1 (en) 2011-10-06
BR112012023836A2 (pt) 2015-09-22
DK2552206T3 (en) 2015-09-28
AU2011235319A1 (en) 2012-10-11
KR20130020666A (ko) 2013-02-27
US20130178459A1 (en) 2013-07-11
MX2012011412A (es) 2013-02-07
US8962648B2 (en) 2015-02-24
TWI503323B (zh) 2015-10-11
JP5849302B2 (ja) 2016-01-27
ES2547571T3 (es) 2015-10-07
JP2013523749A (ja) 2013-06-17
CA2792941A1 (en) 2011-10-06
KR101757502B1 (ko) 2017-07-12
AU2011235319B2 (en) 2016-07-14
EP2552206B1 (en) 2015-07-22
US20150183799A1 (en) 2015-07-02
TW201136939A (en) 2011-11-01

Similar Documents

Publication Publication Date Title
CN102917590B (zh) 三环化合物及含有所述化合物的pbk抑制剂
TWI676619B (zh) 溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑
CN109475531B (zh) Ptpn11的杂环抑制剂
WO2021169990A1 (zh) 用于癌症治疗的kras抑制剂
CN103153063B (zh) 喹啉衍生物及含有其的melk抑制剂
CN110770233B (zh) 稠合双环类化合物及其在药物中的应用
CN104053661B (zh) 非典型性蛋白激酶c的噻吩并嘧啶类抑制剂
CN104768932B (zh) Pde4的杂芳基抑制剂
CN107207464B (zh) 被取代的二氢异喹啉酮化合物
WO2024125642A1 (zh) 含嘧啶多元并环类衍生物抑制剂、其制备方法和应用
CN102471341B (zh) 治疗寄生虫疾病如疟疾的稠合咪唑化合物和含有它们的组合物
TW201512173A (zh) 炔基醇及其使用方法
TW201446758A (zh) 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途
CN107074787A (zh) 赖氨酸特异性脱甲基酶‑1的抑制剂
TW201643153A (zh) 溴結構域抑制劑
CN103781776A (zh) 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物
TW201700477A (zh) 作爲ｐｄｅ１抑制劑之咪唑並吡酮
CN114929708A (zh) 4-[[(7-氨基吡唑并[1,5-a]嘧啶-5-基)氨基]甲基]哌啶-3-醇化合物以及它们的治疗用途
CN115698020A (zh) 大环rip2-激酶抑制剂
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
RU2574398C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-с]ХИНОЛИНА-4-ОНА, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ РВК-ЗАВИСИМОГО ЗАБОЛЕВАНИЯ
HK1179114B (en) Tricyclic compounds and pbk inhibitors containing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant